[EN] PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] ANTAGONISTES DE RECEPTEUR DE LA PROSTAGLANDINE D2 POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
申请人:MILLENNIUM PHARM INC
公开号:WO2005100321A1
公开(公告)日:2005-10-27
Disclosed herein are compounds represented by Structural Formula: (I) and (I-A). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply 'CRTH2' for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.
6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.
Silica-supported terpyridine palladium(II) complex as an efficient and reusable catalyst for Heck and Suzuki cross-coupling reactions
作者:Mostafa M. Amini、Afsaneh Feiz、Minoo Dabiri、Ayoob Bazgir
DOI:10.1002/aoc.3084
日期:2014.2
Silica‐supported terpyridine palladium(II) was prepared and used as an effective and recyclable catalyst in Mizoroki–Heck and Suzuki–Miyaura coupling reactions. The catalyst was very effective for the Mizoroki–Heck reaction of aryl halides with olefins and conversion was in most cases excellent. The catalyst showed good thermal stability (up to 230 °C) and could be recovered and reused for four reaction
PGD2 receptor antagonists for the treatment of inflammatory diseases
申请人:Ghosh Shomir
公开号:US20050256158A1
公开(公告)日:2005-11-17
Disclosed herein are compounds represented by Structural Formula (I) and (I-A):
Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.